Mabpharm Limited (HK:2181) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited has announced structural changes to its leadership team, effective July 10, 2024, including the appointment of Mr. Cen Jialin as a non-executive Director, Dr. Tao Qian as an independent non-executive Director, and the re-designation and promotion of Dr. Qian Weizhu to executive Director and vice president. Additionally, Mr. Li Yunfeng transitions from the CFO to a vice president role. These appointments and re-designations reflect the company’s strategic adjustments in its executive team.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.